PHC and Cyfuse Develop Innovative Production Technology for the Commercialization of 3D Cell Products
PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318287676/en/
(Left) PHC: Cell Expansion System LiCellGrow, (Right) Cyfuse: Bio 3D Printer
The new production technology enables real-time monitoring of the quality of 3D cell products, which are living cells in three-dimensional structures. This type of monitoring, which has been historically challenging for researchers, in turn supports more stable manufacturing of quality cell products. In this collaboration, Cyfuse used its proprietary Bio 3D Printing technology to manufacture 3D cell constructs and PHC used in-line monitoring technology in its LiCellGrowTM(*3) cell expansion system under development to track metabolic activity in the cell constructs. By combining these technologies, the companies successfully improved the quality and stability of 3D cell products during cultivation.
To build on this development, PHC and Cyfuse aim to develop a next-generation type of cell expansion system called a circulation cell culture system that incorporates the new production technology. This new device will seek to identify critical process parameters in the 3D cell product manufacturing process, monitor cell conditions in real time during production, and optimize the manufacturing process based on the state of the cells. The companies hope to contribute to improving the quality and stability of 3D cell products like those Cyfuse develops.
The details of this development will be presented at the 24th Annual Meeting of the Japanese Society for Regenerative Medicine, scheduled to be held at Pacifico Yokohama in Yokohama, Japan from March 20 to March 22, 2025. The companies will showcase their research findings through poster presentations, focusing on the ongoing development of the circulation cell culture system, as well as the quality evaluation of Cyfuse's 3D cell products cultured using this system.
PHC and Cyfuse will continue to advance their joint research efforts to accelerate the practical application of various production technologies. The companies also aim to expand the value chain within the growing field of regenerative and cell therapy. They will seek to promote research and development, technological innovation, and the creation of new products, including Cyfuse’s regenerative medicine products. Furthermore, by strengthening corporate collaboration including strategic partnerships, PHC and Cyfuse are committed to driving growth and advancement in this field through this partnership.
*1 By utilizing PHC's In-Line Monitoring technology, glucose and lactate concentrations in the culture medium can be measured in real time, allowing for automatic medium replacement based on their concentrations to optimize the culture environment. This technology enables precise control of glucose concentration, one of the critical parameters in the culture process of three-dimensional cellular structures, such as Cyfuse’s 3D cell products, to maintain it at the desired level.
*2 For more details, please refer to the press release dated August 2, 2023, titled “PHC Corporation and Cyfuse Biomedical K.K. Enter into Strategic Collaboration Agreement in the Field of Regenerative and Cell Therapy.”
www.phchd.com/jp/phc/news/2023/0802 (Japanese Only)
www.cyfusebio.com/archives/1216 (Japanese Only)
*3 This product, a cell expansion system for research purposes, is currently under development toward commercialization, including potential implementation for medical applications. A prototype of the device was exhibited at "Regenerative Medicine JAPAN 2024" (held in October 2024).
https://www.phchd.com/jp/phc/news/2024/1001 (Japanese only)
About the Biomedical Division of PHC Corporation
Established in 1969, PHC Corporation is a Japanese subsidiary of PHC Holdings Corporation (TOKYO: 6523), a global healthcare company that develops, manufactures, sells, and services solutions across diabetes management, healthcare solutions, life sciences and diagnostics. The Biomedical Division supports the life sciences industry helping researchers and healthcare providers in around 110 countries and regions through its PHCbi-branded laboratory and equipment and services including CO2 incubators and ultra-low temperature freezers.
www.phchd.com/global/phc
About PHC Holdings Corporation (PHC Group)
PHC Holdings Corporation (TOKYO: 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care, Epredia, LSI Medience Corporation, Wemex and Mediford. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, diagnostics and life sciences. PHC Group’s consolidated net sales in FY2023 were JPY 353.9 billion with global distribution of products and services in more than 125 countries.
www.phchd.com/global
About Cyfuse Biomedical K.K.
Cyfuse Biomedical K.K. (Securities Code: 4892, TSE Growth) is a regenerative medicine startup founded in 2010. Using its proprietary bio 3D printing technology, which creates three-dimensional tissues solely from cells without artificial scaffolds, the company develops innovative regenerative medicine products and sells Bio 3D printers, Regenova® and S-PIKE®.
For more information, please visit "CYCHANNEL" at www.cyfusebio.com/cychannel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250318287676/en/
Contacts
Contact for media inquiries:
Investor Relations & Corporate Communications Department
PHC Holdings Corporation
TEL: +81-3-6778-5311
E-mail: phc-pr@gg.phchd.com
Contact for product and service:
Marketing Department, Biomedical Division PHC Corporation
E-mail: masayo.okada@phchd.com
Administration Department, Cyfuse Biomedical K.K.
Email: ir@cyfusebm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
On the International Day of Happiness, Finland Calls for International Business Cooperation to Solve Major Global Challenges Together20.3.2025 02:15:00 EET | Press release
Societal stability, high levels of equality and, among other things, political and civil freedom are frequently highlighted as the key factors contributing to Finland's status as the world’s happiest country in recent years, as reflected in the World Happiness Report. These are the building blocks of the trust and mutual respect that permeate Finnish society, enabling innovative international cooperation and providing an excellent launchpad for business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250319812998/en/ Photo credits: Svante Gullichsen & Visit Finland In Finnish society, there are many factors that underscore succeeding together: an education system that emphasizes teamwork and collective problem-solving, flat hierarchies in organizations and a society that encourages participation, a culture that values consensus and cooperation over individual competition, and social safety nets that provide security, allowin
SoftBank Group to Acquire Ampere Computing20.3.2025 01:30:00 EET | Press release
SoftBank Group Corp. (TSE: 9984, “SoftBank Group”) today announced that it will acquire Ampere® Computing, a leading independent silicon design company, in an all-cash transaction valued at $6.5 billion. Under the terms of the agreement, Ampere will operate as a wholly owned subsidiary of SoftBank Group and retain its name. As part of the transaction, Ampere’s lead investors – Carlyle (NASDAQ: CG) and Oracle Corp. (NYSE: ORCL) – are selling their respective positions in Ampere. As SoftBank Group broadens its AI infrastructure investments in ventures such as Cristal intelligence and Stargate, the acquisition will help enhance SoftBank Group’s capabilities in key areas and accelerate its growth initiatives. “The future of Artificial Super Intelligence requires breakthrough computing power,” said Masayoshi Son, Chairman and CEO of SoftBank Group Corp. “Ampere’s expertise in semiconductors and high-performance computing will help accelerate this vision, and deepens our commitment to AI inn
Verimatrix Launches XTD Velocity Partner Alliance to Accelerate Global Channel Sales19.3.2025 18:45:00 EET | Press release
Regulatory News: Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced the launch of the Verimatrix XTD Velocity Partner Alliance, a global channel sales program designed to empower partners with best-in-class application protection solutions. As part of this initiative, Risk Associates, a leading Managed Security Services Provider (MSSP), has joined the program to offer Verimatrix XTD Enterprise Suite to banks and enterprises across Australia, Bahrain, Saudi Arabia, and the UAE. The XTD Velocity Partner Alliance, spearheaded by Simon Emery, Global Head of Strategic Partnerships at Verimatrix, provides resellers, MSSPs, system integrators, and cybersecurity firms with comprehensive resources to deliver AI-powered mobile app shielding, endpoint threat detection, and response solutions. The program enhances channel sales by offering: Resell XTD & Deliver Managed Services – Offer 24/7 app hardening with AI-drive
Unity Announces Enhanced Engine Performance and Stability, New Platforms, and AI-Powered Workflows at GDC 202519.3.2025 18:00:00 EET | Press release
GDC – Unity (NYSE: U), the leading platform to create and grow games and interactive experiences, today announced that developers can expect enhanced performance and stability, expanded platform support, and new AI-powered workflows in the three Unity 6 Updates planned for 2025, with the first, Unity 6.1, landing in April. “We don’t want developers to have to choose between stability and new features, or between fidelity and ubiquity. We are committed to delivering it all," said Matt Bromberg, CEO and President of Unity. “Pressure testing new releases in production environments with our partners is enabling much higher quality builds.” Unity 6.1 will enable higher frame rates, smoother gameplay, lower CPU/GPU load for better device performance, and improved debugging for easier optimization. Additionally, Unity is doubling down on its platform reach, extending Unity 6.1’s platform support beyond the current 20+ platforms to include large and foldable Android screens, Meta Quest, Androi
Venture Global Receives Non-FTA Export Authorization for CP2 LNG19.3.2025 16:55:00 EET | Press release
Today, Venture Global received approval from the U.S. Department of Energy to export liquefied natural gas (LNG) to non-FTA countries for its third project, CP2 LNG, located in Cameron Parish, Louisiana. Venture Global CEO Mike Sabel issued the following statement: “CP2 LNG is a vital project for the U.S. economy, balance of trade, and global energy security. We are grateful for the Trump Administration’s return to regular order and regulatory certainty that will allow us to further expand U.S. LNG exports, which have consistently been found to be in the public interest across multiple Administrations. This will enable us to provide our allies around the world with American LNG in just a few years and for decades to come.” Earlier this month, Venture Global announced that it has launched the FID process for CP2 LNG. To date, the initial phase of CP2 LNG has been sold through 20-year sales and purchase agreements with ExxonMobil, Chevron, JERA, New Fortress Energy, INPEX, China Gas, SEF
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom